Pharming Technologies
Clinical trials sponsored by Pharming Technologies, explained in plain language.
Now part of
Pharming Group N.V.
PHAR
NASDAQ
A biopharmaceutical company developing treatments for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise for rare immune disorder in early trial Results expected Oct 2026 (estimated)
- New drug aims to calm overactive immune system in rare disorders Results expected Nov 2026 (estimated)
- New hope for kids with rare immune disease: drug targets root cause Results expected Nov 2026 (estimated) 🚀 Make-or-break